|
所属 |
大学院医学系研究科（医学専攻等） 医学専攻 腫瘍制御医学系 腎泌尿器科学講座 |
|
生年 |
1974年 |
職務経歴（学内） 【 表示 ／ 非表示 】
-
2020年05月-継続中
秋田大学 大学院医学系研究科（医学専攻等） 医学専攻 腫瘍制御医学系 准教授
-
2017年01月-2020年04月
秋田大学 附属病院 血液浄化療法部 准教授
-
2011年01月-2016年12月
秋田大学 附属病院 泌尿器科 講師
研究等業績 【 表示 ／ 非表示 】
-
Genetic variations predicting progression with docetaxel and novel androgen-receptor pathway inhibitors.
Masaki Shiota, Shusuke Akamatsu, Yuya Sekine, Hiroko Kimura, Shintaro Narita, Naohiro Fujimoto, Naoki Terada, Leandro Blas, Tomonori Habuchi, Toshiyuki Kamoto, Yukihide Momozawa, Masatoshi Eto
Cancer science 2023年01月
研究論文（学術雑誌）
Genetic variations represented by single-nucleotide polymorphisms (SNPs) could be helpful for choosing an effective treatment for patients with prostate cancer. This study investigated the prognostic and predictive values of SNPs associated with the prognoses of pharmacotherapy for prostate cancer through their pharmacological mechanisms. Patients treated with docetaxel or androgen receptor pathway inhibitors (ARPIs), such as abiraterone and enzalutamide, for castration-resistant prostate cancer were included. The SNPs of interest were genotyped for target regions. The prognostic and predictive values of the SNPs for time to progression (TTP) were examined using the Cox hazard proportional model and interaction test, respectively. Rs1045642 in ABCB1, rs1047303 in HSD3B1, rs1856888 in HSD3B1, rs523349 in SRD5A2, and rs34550074 in SLCO2A1 were differentially associated with TTP between docetaxel chemotherapy and ARPI treatment. In addition to rs4775936 in CYP19A1, rs1128503 in ABCB1 and rs1077858 in SLCO2B1 might be differentially associated with TTP between abiraterone and enzalutamide treatments. Genetic predictive models using these SNPs showed a differential prognosis for treatments. This study identified SNPs that could predict progression as well as genetic models that could predict progression when patients were treated with docetaxel versus ARPI and abiraterone versus enzalutamide. The use of genetic predictive models is expected to be beneficial in selecting the appropriate treatment for the individual patient.
-
Outcome of right hand-assisted retroperitoneoscopic living donor nephrectomy
Narita S， et al
Urology 67 ( 3 ) 496 - 500 2006年03月 [査読有り]
研究論文（学術雑誌） 国内共著
-
Modified M-VAC療法後に残存腫瘍切除を施行した進行尿路上皮癌患者の治療成績
成田伸太郎他
泌尿器紀要 51 155 - 158 2005年01月
研究論文（学術雑誌） 国内共著
-
前立腺癌におけるLPL遺伝子多型の検討
成田伸太郎、土谷順彦、王立忠
日本腎泌尿器予防医学研究会誌 13 82 - 83 2005年01月
研究論文（学術雑誌） 国内共著
-
Association of lipoprotein lipase gene polymorphism with risk of prostate cancer in a Japanese population
Narita S， Tsuchiya N， Wang L， Matsuura S， Ohyama C， Satoh S， Sato K， Ogawa O ， Habuchi T and Kato T
Int J cancer 112 872 - 876 2004年01月 [査読有り]
研究論文（学術雑誌） 国内共著
-
Numakura K.
World Journal of Surgical Oncology ( World Journal of Surgical Oncology ) 20 ( 1 ) 202 - 202 2022年12月
INTRODUCTION: Warm ischemia time (WIT) is a primary concern for robot-assisted laparoscopic partial nephrectomy (RALPN) patients because longer WIT is significantly associated with postoperative deteriorating kidney function. Tumor complexity, determined by the RENAL nephrometry score (RENAL score), can help predict surgical outcomes, but it is unclear what RENAL score and clinical factors affect WIT. This study explored the clinical factors predicting long WIT in experienced surgeon to RALPN. MATERIALS AND METHODS: In our institute, 174 RALPNs were performed between November 2013 and February 2021, of which 114 were performed by a single surgeon and included in this study. Clinical staging and the total RENAL score were determined based on preoperative CT scans. The cases were divided into three groups based on experience: period 1: 1-38, period 2: 39-76, and period 3: 77-114. The clinical factors associated with longer WIT were analyzed per period. RESULTS: The overall median tumor diameter was 32 mm, and one patient had a positive surgical margin, but there were no cancer-related deaths. In total, there were 18 complications (15.8%). Periods 2 and 3 had larger tumor diameters (p < 0.01) and worse preoperative kidney function (p = 0.029) than period 1. A RENAL L-component score of 3 was associated with longer WIT in period 3 (odds ratio: 3.900; 95% confidence interval: 1.004-15.276; p = 0.044), but the tumor diameter and the total RENAL score were not. CONCLUSIONS: A large tumor in the central lesion indicated by the RENAL L-component score was associated with increased WIT in RALPN.
-
Kimura H.
British Journal of Cancer ( British Journal of Cancer ) 127 ( 9 ) 1680 - 1690 2022年11月
BACKGROUND: The prognostic significance of germline variants in homologous recombination repair genes in advanced prostate cancer (PCa), especially with regard to hormonal therapy, remains controversial. METHODS: Germline DNA from 549 Japanese men with metastatic and/or castration-resistant PCa was sequenced for 27 cancer-predisposing genes. The associations between pathogenic variants and clinical outcomes were examined. Further, for comparison, DNA from prostate biopsy tissue samples from 80 independent patients with metastatic PCa were analysed. RESULTS: Forty-four (8%) patients carried germline pathogenic variants in one of the analysed genes. BRCA2 was most frequently altered (n = 19), followed by HOXB13 (n = 9), PALB2 (n = 5) and ATM (n = 5). Further, the BRCA1, BRCA2, PALB2 and ATM variants showed significant association with a short time to castration resistance and overall survival (hazard ratio = 1.99 and 2.36; 95% CI, 1.15-3.44 and 1.23-4.51, respectively), independent of other clinical variables. Based on log-rank tests, the time to castration resistance was also significantly short in patients with BRCA1, BRCA2, PALB2 or ATM somatic mutations and TP53 mutations. CONCLUSIONS: Germline variants in BRCA1, BRCA2, PALB2 or ATM are independent prognostic factors of the short duration of response to hormonal therapy in advanced PCa.
-
Narita S.
International Journal of Urology ( International Journal of Urology ) 29 ( 10 ) 1147 - 1154 2022年10月
OBJECTIVE: This study aimed to assess survival outcomes in older patients with de novo metastatic prostate cancer who initially received androgen deprivation therapy. METHODS: The retrospective multicenter study included 2784 men with metastatic prostate cancer who were treated with androgen deprivation therapy between 2008 and 2017. Patients were classified into <75, 75-79, and ≥80 age groups. Propensity score matching was conducted to assess the cancer-specific survival of the groups. The 5-year net overall survival of each group was derived to evaluate relative survival compared with the general population using the Pohar-Perme estimator and the 2019 Japan Life Table. RESULTS: During the follow-up (median, 34 months), 1014 patients died, of which 807 died from metastatic prostate cancer progression. Compared with the <75 group, the cancer-specific survival of the 75-79 group was similar (hazard ratio 1.07; 95% confidence interval 0.84-1.37; P = 0.580), whereas that of the ≥80 group was significantly worse (hazard ratio 1.41; 95% confidence interval 1.10-1.80; P = 0.006). The 5-year net overall survival of the <75, 75-79, and ≥80 age groups were 0.678, 0761, and 0.718, respectively. The 5-year net overall survival of patients aged ≥80 years with low- and high-volume disease were 0.893 and 0.586, respectively, which was comparable with those in patients aged <75 years (0.872 and 0.586, respectively). CONCLUSIONS: Older metastatic prostate cancer patients aged ≥80 years had poorer cancer-specific survival compared with younger patients. Conversely, 5-year net overall survival in older patients aged ≥80 years was comparable with that in younger patients aged <75 years.
-
Yanagisawa T.
Prostate ( Prostate ) 82 ( 14 ) 1322 - 1330 2022年10月
BACKGROUND: Docetaxel-related adverse events (AEs) such as neutropenia and febrile neutropenia (FN) can be life-threatening. A previous in vivo study raised the hypothesis that the castration status affects the rate of hematologic AEs. We aimed to investigate the impact of castration status on the incidence of docetaxel-related AE in metastatic prostate cancer (mPCa) patients. METHODS: We retrospectively analyzed the records of 265 mPCa patients treated with docetaxel, comprising 92 patients with metastatic hormone-sensitive prostate cancer (mHSPC) and 173 patients with metastatic castration-resistant prostate cancer (mCRPC) between January 2015 and December 2021. Common terminology Criteria for Adverse Events (CTCAE) was applied to evaluate AEs. We analyzed the differential incidences between mHSPC and mCRPC, and risk factors of hematologic and nonhematologic AEs using a logistic regression model. RESULTS: The rate of patients who received primary prophylaxis against neutropenia was higher in those with the mHSPC compared with those with the mCRPC (7.5% vs. 33%, p < 0.001). Among the patients without primary prophylaxis, incidence rates of severe neutropenia (CTCAE ≥ Grade3) and FN were 89% and 16% in patients with mCRPC compared to 81% and 18% in those with mHSPC. Logistic regression analysis revealed that age ≥ 75 years and failure to provide primary prophylaxis were independent risk factors of severe neutropenia (odds ratio [OR]: 2.39, 95% confidential interval [CI]: 1.10-5.18 and OR: 15.8, 95% CI: 7.23-34.6, respectively). Eastern Cooperative Oncology Group Performance Status (ECOG-PS) ≧ 1 was an independent risk factor of FN (OR: 2.26, 95% CI: 1.13-4.54). Castration status (mHSPC vs. mCRPC) was not associated with the risks of severe neutropenia and FN. CONCLUSIONS: Castration status did not affect the risk of severe neutropenia or FN in mPCa patients treated with docetaxel regardless of the disease state. Failure to provide primary prophylaxis and advanced patient age are independent risk factors of severe neutropenia; while patients with poor PS are more likely to develop FN. These findings may help guide the clinical decision-making for proper candidate selection of docetaxel treatment.
-
特集 限局性前立腺癌診療バイブル-このへんでキッチリと前立腺癌診療の"あたりまえ"を整理しよう! 〈高齢者・その他〉 高齢者限局性前立腺癌治療
成田 伸太郎
臨床泌尿器科 ( 株式会社医学書院 ) 76 ( 11 ) 844 - 850 2022年10月
◆原著論文【 表示 ／ 非表示 】
◆その他【 表示 ／ 非表示 】
学術関係受賞 【 表示 ／ 非表示 】
-
Best Presentation Award of the ACRLS 2022
2022年12月 Asian-Pacific Congress of Robotic Laparoscopic Surgery Best Presentation Award of the ACRLS 2022
受賞者： Shintaro Narita -
優秀演題賞
2022年10月 第60回日本癌治療学会学術集会 優秀演題賞
受賞者： 成田伸太郎
学会等発表 【 表示 ／ 非表示 】
-
Sekine Y.
Japanese journal of clinical oncology 2022年12月 - 2022年12月 Japanese journal of clinical oncology
-
特集 限局性前立腺癌診療バイブル-このへんでキッチリと前立腺癌診療の"あたりまえ"を整理しよう! 〈高齢者・その他〉 高齢者限局性前立腺癌治療
成田 伸太郎
臨床泌尿器科 2022年10月 - 2022年10月 株式会社医学書院
-
Nagumo Y.
International Journal of Urology 2022年05月 - 2022年05月 International Journal of Urology
-
秋田大学における腎移植後貧血に対するHIF-PH阻害薬の初期使用経験
山本 竜平, 齋藤 満, 青山 有, 藤山 信弘, 提箸 隆一郎, 小林 瑞貴, 嘉島 相輝, 奈良 健平, 沼倉 一幸, 成田 伸太郎, 羽渕 友則
移植 2022年 - 2022年 一般社団法人 日本移植学会
<p>【目的】腎移植後貧血(PTA)に対する治療は長年エリスロポエチン製剤 (ESA)が主体であったが、ESA抵抗性貧血を呈する症例も存在する。近年、ESA抵抗性PTAに対するHypoxia Inducible Factor-Prolyl Hydroxylase (HIF-PH)阻害薬の有効性が報告されている。当院ではHIF-PH阻害薬の適応をESA高用量でも貧血が改善しない症例、および受診間隔延長によりESAの効果が乏しい症例としている。今回、当院でHIF-PH阻害薬を使用した20例について検討をおこなった。</p><p>【対象と方法】腎移植後に当院でHIF-PH阻害薬投与歴のある20例を対象とし、HIF-PH阻害薬投与投与開始後前の背景や投与開始後の臨床因子を後方視的に検討した。</p><p>【結果】年齢平均値50歳、男性８例、女性12例、移植後平均年数は6.9年、19例がESAからの切り替えであった。開始後1、3、6ヶ月時点で投与継続中の症例はそれぞれ18、10、6例であり、有害事象で投与中止となった症例は２例でいずれも消化器症状であった。また１例は悪性腫瘍の発症により中止となった。HIF-PH阻害薬開始前の平均ヘモグロビン(Hb)値9.4 g/dL、平均血清Fe値96μg/dL、平均TSAT38.6％、平均フェリチン値203ng/ml であった。1、3、6ヶ月継続症例の平均Hbはそれぞれ9.6、10.6、10.8 g/dLであり、3、6ヶ月継続時点で有意な増加を認めた(p<0.05)。平均血清鉄値に有意な変化はみられなかったが、TSATは1、3、6ヶ月継続群すべてで上昇を認め、フェリチン値は3、6ヶ月継続群で減少傾向であった。</p><p>【結語】ESA抵抗性PTA症例において、HIF-PH阻害薬の導入により鉄利用能改善さらには貧血の改善が期待できる。</p>
-
Ozaki K.
World Journal of Urology 2022年 - 2022年 World Journal of Urology